Cargando…

Analysis of clinical efficacy of CyberKnife(®) treatment for locally advanced pancreatic cancer

OBJECTIVE: To evaluate the efficacy and safety of CyberKnife(®) treatment for locally-advanced pancreatic cancer (LAPC). METHODS: The efficacy of CyberKnife(®) treatment was analyzed in 59 LAPC patients treated between October 2006 and September 2014. The median tumor volume was 27.1 mL (13.0–125.14...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yongchun, Yuan, Zhiyong, Li, Fengtong, Dong, Yang, Zhuang, Hongqing, Wang, Jingsheng, Chen, Huaming, Wang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472027/
https://www.ncbi.nlm.nih.gov/pubmed/26109866
http://dx.doi.org/10.2147/OTT.S81939
Descripción
Sumario:OBJECTIVE: To evaluate the efficacy and safety of CyberKnife(®) treatment for locally-advanced pancreatic cancer (LAPC). METHODS: The efficacy of CyberKnife(®) treatment was analyzed in 59 LAPC patients treated between October 2006 and September 2014. The median tumor volume was 27.1 mL (13.0–125.145 mL). The median prescribed dose was 45 Gy (35–50 Gy), delivered in 5 fractions (3–8 fractions). The overall survival (OS) rates and freedom from local progression (FFLP) rates were estimated using the Kaplan–Meier survival curve. RESULTS: The median follow-up for all patients was 10.9 months (3.2–48.7 months) and 15.6 months (3.9–37.6 months) among surviving patients. The median OS was 12.5 months, and the 1-year and 2-year survival rates were 53.9% and 35.1%, respectively. The 1-year FFLP rate was 90.8% based on the computed tomography (CT) evaluation. Grade 1–2 acute and late-stage gastrointestinal (GI) reactions were observed in 61% of the patients. One patient experienced grade 3 toxicity. CONCLUSION: Excellent clinical efficacy was obtained after treatment of LAPC using CyberKnife(®), with minimal toxicity.